Preliminary Scientific Program

Print
Hall C


Exhibition Hall – Thursday 5th November, 2015
 
19:00-20:00
Welcome Reception


Hall C - Friday 6 November, 2015
 
Session 4
09:00-10:30
Patients with Type 2 Diabetes Failing Intense Insulin Therapy (MDI)
  09:00-09:05  Chairpersons I. Satman, Turkey and E. Standl, Germany

 
09:05-09:30
Further treating to target
H. Ilkova, Turkey

 
 

09:30-09:55
09:55-10:20
Patient with Type 2 DM failing insulin therapy:
Adding GLP1: B. Charbonnel, France
Insulin pump: O. Cohen, Israel
  10:20-10:30 Discussion
 
10:30-11:00
Coffee Break
 
Session 7
11:00-12:30
Heart Failure in Type 2 Diabetes
  11:00-11:05 Chairpersons: E. Taşan, Turkey and M. Theodorakis, UK
 
 
11:05-11:30 
Antidiabetic drugs and heart failure
N. Lalic, Serbia
 
 
11:30-11:55
11:55-12:20 
DPP-4 inhibitors and heart failure
Risk exceeds benefit: G. Schernthaner, Austria
Benefit exceeds risk: A. Cahn, Israel
  12:20-12:30 Discussion
 
12:30-12:40
Lunchbox Pick Up
  
12:40-13:50
Industrial Satellite Symposium
 
13:50-14:10
Coffee & Dessert
 
Session 10
14:10-15:40
Establishing Safety of New Therapies After Licensing
14:10-14:15
Chairpersons: A. Kaya, Turkey and B. Itzhak, Israel

14:15-14:40 
Why do EMA and FDA so often disagree?
P. Pozzilli, Italy

14:40-15:05
What should 'efficacy' mean for new glucose-lowering medication?
P. Home, UK

15:05-15:30
Cost effectiveness of therapy - of individual care or of overall care?
L. Van Gaal, Belgium
15:30-15:40 Discussion
 
Session 13
15:40-17:10
Lipids
 
15:40-15:45
Chairperson: M. Özyazar, Turkey and V. Lyssenko, Sweden
 
 
 
15:45-16:00
16:00-16:15
15:15-15:25 
Lipid treatment in type 2 diabetic patients: Statin-based or target based?
Satin Based: M. R. Taskinen, Finland
Target Based: A. Zambon, Italy
Discussion

 
16:25-16:40
16:40-16:55
16:55-17:10 
Remembering statins: Do statins have adverse cognitive effects?
No: R. Bitzur, Israel
Yes: T. Cukierman-Yaffe, Israel
Discussion

17:10-17:30
Coffee Break

17:30-19:00
Industrial Satellite Symposium